Patents by Inventor Herbert Sindermann

Herbert Sindermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
    Patent number: 10288629
    Abstract: The present invention provides a method for measuring growth hormone level in a human or animal subject, including a method of assessing pituitary-related growth hormone deficiency in a human or animal subject, after macimorelin oral administration to the subject.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: May 14, 2019
    Assignee: Aeterna Zentaris, Inc.
    Inventors: Nicola Ammer, Gilbert Muller, Richard Sachse, Herbert Sindermann
  • Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8551977
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolite antitumor substances for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or more antimetabolite antitumor substances. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: October 8, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jurgen Engel, Eckhard Gunther, Herbert Sindermann
  • Use of perifosine in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8507710
    Abstract: The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: August 13, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jurgen Engel, Eckhard Gunther, Herbert Sindermann
  • Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8389497
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or a combination of various approved cytostatics. Preferred alkylphosphocholines are described by the Formula II.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: March 5, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann
  • Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
    Patent number: 8383605
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: February 26, 2013
    Assignee: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann, Babette Aicher
  • Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
    Publication number: 20110028421
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolites for the treatment of multiple myeloma, colon cancer or renal cancer. Preferred alkylphosphocholines are described by the Formula II. A particularly effective treatment includes administering a combination of perifosine and capecitabine.
    Type: Application
    Filed: March 31, 2010
    Publication date: February 3, 2011
    Applicant: AEterna Zentaris GmbH
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann, Babette Aicher
  • Use of Alkylphophocholine in Combination with Antitumor Medication for the Treatment of Benign and Malignant Oncoses in Humans and Mammals
    Publication number: 20100189784
    Abstract: The invention relates to pharmaceutical compositions comprising alkylphosphocholines and antimetabolite antitumor substances. The pharmaceutical compositions of the invention are useful for the treatment of benign and malignant oncoses in humans and animals. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 29, 2010
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann
  • Use of Aalkylphophocholines in Combination with Antitumor Medication for the Treatment of Benign and Melignant Oncoses in Humans and Mammals
    Publication number: 20100190738
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antimetabolite antitumor substances for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or more antimetabolite antitumor substances. Preferred alkylphosphocholines are described by the Formula II. One such preferred alkylphosphocholine is perifosine.
    Type: Application
    Filed: March 31, 2010
    Publication date: July 29, 2010
    Inventors: Jürgen Engel, Eckhard Günther, Herbert Sindermann
  • Use of alkylphosphocholines in combination with antitumor medications for the treatment of benign and malignant oncoses in humans and mammals
    Publication number: 20040097470
    Abstract: The invention relates to the use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals. It is possible in this connection for the alkylphosphocholines to be employed in a combination according to the invention with one or a combination of various approved cytostatics. Preferred alkylphosphocholines are described by the Formula II.
    Type: Application
    Filed: July 30, 2003
    Publication date: May 20, 2004
    Inventors: Jurgen Engel, Eckhard Gunther, Herbert Sindermann